Fracture liaison service (FLS) is associated with lower subsequent fragility fracture risk and mortality: NoFRACT (the Norwegian capture the fracture initiative).

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethical approval: All procedures performed in the study were in accordance with the 1964 Helsinki Declaration and its later amendments. The study was approved by the Regional Committee of Medical and Health Research Ethics (REK 2015/334). The merging of data using the personal identification number and exemption from obtaining consent for the collection of data was approved by the Regional Committee of Medical and Health Research Ethics (REK 2015/334). A Data Protection Impact Assessment (DPIA) in agreement with the General Data Protection Regulation was performed by The University of Oslo. The study was approved by the Patient Data Protection Officer (PVO) at each of the hospitals and the PVO provided exemption from obtaining consent from the participants and authorized a secure research server for storage of the audit data. Conflict of interest: CA, CD, TB, TW, GH, JMS, IL, AKH, FIN, LN, TKO, and ÅB no support from any organization for the submitted work; FF reports lecturing fees from UCB and Amgen; TTB reports speaker fees from UCB, Amgen, Roche Diagnostics, and Pharma Prim and participation in an advisory board for UCB. Further, FF is president of the Fragility Fracture Network which is sponsored by Amgen, UCB, and Danone; JEG reports lecture fees from Ortomedic Norway, Smith and Nephew, Heraeus Medical, and LINK Norway; WF reports lecture fees from Ortomedic Norway and Zimmer Biomet Norway; EMA reports participation in the advisory board for UCB and Amgen; RMJ reports consulting fees from Norwegian Directorate of Health, Norwegian Diabetes Association, and Northern Norway Regional Health Authority and lecture fees from Novo Nordisk, Eli-Lilly, Astra-Zeneca, and Sanofi; US reports speaker and consulting fees from Amgen, UCB, and Novartis; EFE reports consultant fees from Novartis, UCB, Amgen, Takeda, and Pharma Medico and research support from Takeda and Amgen. Further, EFE has worked as a medical consultant for the Norwegian Osteoporosis Society; LBS reports speaker fees from Eli Lilly, Amgen, and UCB. Further, LBS is the president of Fragility Fracture Network Norway.